首页> 外文期刊>The journal of immunology >Anti-Human CD73 Monoclonal Antibody Inhibits Metastasis Formation in Human Breast Cancer by Inducing Clustering and Internalization of CD73 Expressed on the Surface of Cancer Cells
【24h】

Anti-Human CD73 Monoclonal Antibody Inhibits Metastasis Formation in Human Breast Cancer by Inducing Clustering and Internalization of CD73 Expressed on the Surface of Cancer Cells

机译:抗人CD73单克隆抗体通过在癌细胞表面上表达CD73的聚类和内化抑制人乳腺癌中的转移形成

获取原文
           

摘要

Recent studies have shown that Abs that target the cell-surface enzyme CD73 (ecto-5′-nucleotidase) reduce growth of primary tumors and metastasis in syngenic mice by inhibiting the catalytic activity of CD73, and thus increasing the activity of cytotoxic T lymphocytes. In this article, we report another anticancer mechanism of anti-CD73 Abs and show that an anti-CD73 mAb (AD2) inhibits metastasis formation by a mechanism independent of CD73 catalytic activity and inhibition of primary tumor growth. This mechanism involves clustering and internalization of CD73, but does not require cross-linking of CD73, because both whole IgG anti-CD73 AD2 mAb and Fab′ fragments thereof exhibited this effect. Ex vivo treatment of different breast cancer cell lines with anti-CD73 AD2 mAb before i.v. injection into mice inhibited extravasation/colonization of circulating tumor cells and significantly reduced metastasis development. This effect was also observed when the cancer cell-surface expression of CD73 was significantly reduced by small interfering RNA knockdown. The antimetastatic activity is epitope specific, as another Ab that efficiently binds CD73-expressing live cancer cells did not lead to CD73 internalization and metastasis inhibition. Furthermore, anti-CD73 AD2 mAb inhibited development of metastasis in a spontaneous animal model of human metastatic breast cancer. Our study shows that some anti-CD73 mAbs cause cell-surface clustering of CD73 followed by internalization, thus inhibiting the ability of circulating tumor cells to extravasate and colonize, leading to inhibition of metastasis. Ab-based CD73 cancer therapy should include a combination of Abs that target the catalytic activity of CD73, as well as those with the characteristics described in this article. This article is featured in In This Issue , p.[3971][1] [1]: /lookup/volpage/191/3971
机译:最近的研究表明,通过抑制CD73的催化活性,靶向细胞表面酶CD73(ECTO-5'-核苷酸酶)的ABS将靶向细胞表面酶CD73(ECTO-5'-核苷酸酶)减少生成小鼠中原发性肿瘤和转移的生长,从而增加细胞毒性T淋巴细胞的活性。在本文中,我们报告了抗CD73 ABS的另一种抗癌机制,并表明抗CD73 MAB(AD2)通过独立于CD73催化活性和抑制原发性肿瘤生长的机制来抑制转移形成。该机制涉及CD73的聚类和内化,但不需要CD73的交联,因为整个IgG抗CD73 AD2 mAb和其晶片的片段表现出这种效果。在I.V之前与抗CD73 AD2 mAb进行不同乳腺癌细胞系的exVi​​vo治疗。注射成小鼠抑制循环肿瘤细胞的渗入/定植,并显着降低转移发育。当小干扰RNA敲低显着降低CD73的癌细胞表面表达时,还观察到这种效果。抗致抗体活性是表位特异性,因为另一个有效结合CD73的活癌细胞的AB,没有导致CD73的内化和转移抑制。此外,抗CD73 AD2 MAb在人转移性乳腺癌的自发动物模型中抑制转移的发展。我们的研究表明,一些抗CD73 mAb引起CD73的细胞表面聚类,然后导致内化,从而抑制循环肿瘤细胞外腐蚀和殖民的能力,导致转移抑制。基于AB的CD73癌症疗法应包括ABS的组合,其靶向CD73的催化活性,以及​​具有本文中描述的特性的ABS的组合。本文在本问题中介绍,p。[3971] [1] [1]:/查找/ volpage / 191/3971

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号